Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Soleno Therapeutics (SLNO) Interest & Investment Income (2017 - 2025)

Soleno Therapeutics (SLNO) has disclosed Interest & Investment Income for 4 consecutive years, with $5.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Interest & Investment Income changed N/A to $5.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $17.0 million, a N/A change, with the full-year FY2025 number at $17.0 million, up 40.66% from a year prior.
  • Interest & Investment Income was $5.1 million for Q4 2025 at Soleno Therapeutics, down from $5.3 million in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $5.3 million in Q3 2025 to a low of $3.2 million in Q2 2025.